Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
|Mansoura University, Egypt|
|ScientificTracks Abstracts: J Clin Exp Ophthalmol|
|Purpose: To determine the effect of a topical dorzolamide 2% on the macular thickness and function in patients with diabetic cystoid macular edema (CME). Setting: Mansoura Ophthalmic Center, Mansoura University, Mansoura, Egypt. Methods: The study was planned as a prospective, non-randomized, controlled and interventional study. A total of 84 diabetic patients (93 eyes) with secondary cystoid macular edema were included in the study. All eyes received topical dorzolamide 2% every 8 hours/day for one month. Changes in best-corrected visual acuity (BCVA), intraocular pressure (IOP), and optical coherence tomography measurements were evaluated at one week, one month and 3 months post-treatment. Results: Mean (logMAR) best-corrected visual acuity pre-treatment and one week, 1 month, and 3 months post-treatment was 1.08±0.26, 1.02±0.28, 0.66±0.24 and 0.87±0.26, respectively. The mean baseline central macular thickness was 535.27 ± 97.4 μm and reduced to 420.87±115.24 μm (21.4% reduction) at one week and 357.43±125.8 μm (33.2% reduction) at one month and then showed slight increase and reached 376.23±134.5 μm (29.7% reduction) at the end of 3 months, but still statistically significantly less than the baseline value. Conclusions: Topical dorzolamide 2% significantly improved BCVA and reduced mean central macular thickness at 3 months. It could be effective, affordable and safe therapy in treating non-refractory diabetic cystoids macular edema.|
Amani Badawi has completed her PhD in 2012 from Mansoura University, Egypt. She has worked as an Assistant Lecturer of Ophthalmology, Mansoura Ophthalmic Center in Egypt from 2006-2012 and as a Lecturer of Ophthalmology in Mansoura Ophthalmic Center in Egypt from 2012 to till date. She has published three papers and has been serving as a Reviewer in two different journals.
Email: [email protected]
|PDF | HTML|